%0 Journal Article
%A Fanciulli, Chiara
%A Berenguer, Juan
%A Busca, Carmen
%A Vivancos, María J
%A Téllez, María J
%A Domínguez, Lourdes
%A Domingo, Pere
%A Navarro, Jordi
%A Santos, Jesús
%A Iribarren, José A
%A Morano, Luis
%A Artero, Arturo
%A Moreno, Javier
%A Rivero-Román, Antonio
%A Santos, Ignacio
%A Giner, Livia
%A Armiñanzas, Carlos
%A Montero, Marta
%A Manzardo, Christian
%A Cifuentes, Carmen
%A García, Coral
%A Galindo, María J
%A Ferrero, Oscar L
%A Sanz, José
%A de la Fuente, Belén
%A Rodríguez, Carmen
%A Gaspar, Gabriel
%A Pérez, Laura
%A Losa, Juan E
%A Force, Luis
%A Veloso, Sergio
%A Martínez-Alfaro, Elisa
%A Jarrín, Inmaculada
%A De Miguel, Marta
%A González Garcia, Juan
%A GeSIDA 8514 Study Group
%T Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
%D 2022
%U http://hdl.handle.net/10668/19960
%X We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p  In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population.
%K HIV infection/*epidemiology
%K coinfection/*epidemiology
%K hepatitis C/drug therapy/*epidemiology
%~